EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Treatment of Pediatric, Adolescent, and Young Adult Patients With Fusion‐Positive Alveolar Rhabdomyosarcoma Infiltrating Regional Lymph Nodes in the European CWS‐2002P and RMS 2005 Studies and the Soft Tissue Sarcoma Registry

Amadeus T Heinz iD, Melissa Ciuffolotti, Johannes H M Merks, Anton Schönstein, Véronique Minard-Colin iD, Jörg Fuchs, Gabriela Guillen, Beate Timmermann, Christian Vokuhl iD, Ewa Koscielniak iD, Julia C Chisholm iD, Monika Sparber-Sauer iD and 1 more

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31476 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2025. Written by Amadeus T Heinz and 12 co-authors. Institution: Department of Pediatric Hematology and Oncology, University Children´s Hospital Tuebingen, Tuebingen, Germany. Major MEDLINE topics: Rhabdomyosarcoma, Alveolar, Registries, Antineoplastic Combined Chemotherapy Protocols, Lymph Nodes. Cited 6 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Fondazione Città della Speranza, Alice's Arc, Deutsche Kinderkrebsstiftung.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Patients with alveolar rhabdomyosarcoma (ARMS) with regional lymph node involvement (N1) are defined as “very‐high‐risk rhabdomyosarcoma” in Europe. Different chemotherapy regimens were used in European study protocols.

Methods

Patients with FOXO1 fusion‐positive N1 ARMS registered in the CWS‐2002P study, the EpSSG RMS 2005 study, and SoTiSaR were retrospectively investigated. Patients received systemic treatment with chemotherapy (CHT) and local treatment of primary tumor (PT) and involved lymph nodes (LN) with radiotherapy (RT) and/or surgery. Kaplan–Meier estimators and Cox regression were used to examine event‐free survival (EFS) and overall survival (OS) according to prognostic factors and treatment.

Results

A total of 156 patients registered in RMS 2005 ( n = 99), CWS‐2002P ( n = 20), and SoTiSaR ( n = 37) between 2003 and 2020 were eligible for this analysis. Median age at diagnosis was 10.2 years [0.1–21.9]. Treatment comprised CHT with IVADo (ifosfamide, vincristine, actinomycin‐D, doxorubicin, n = 93; 60%), VAIA (vincristine, actinomycin‐D, ifosfamide, adriamycin/doxorubicin, n = 53; 34%) or other regimens ( n = 10; 6%); resection of the PT ( n = 89; 57%), LN sampling or dissection ( n = 92; 59%), and/or RT ( n = 139; 89%). Maintenance treatment (MT) was added in n = 99/135 (73%) patients who achieved complete remission. Five‐year EFS and OS of the cohort were 45% and 47%, respectively. Age and tumor size were independent prognostic factors for EFS. Local treatment applied to the LN with surgery, RT or both significantly improved EFS ( p = 0.02) and OS ( p = 0.04), with no difference between the modalities ( p = 0.7).

Conclusions

Patients with fusion‐positive N1 ARMS carry a poor prognosis. Adequate local treatment of LN improved survival.

Subjects

MeSH terms (MEDLINE)

Rhabdomyosarcoma, AlveolarRegistriesAntineoplastic Combined Chemotherapy ProtocolsLymph NodesOncogene Proteins, FusionHumansAdolescentMaleFemaleChildYoung AdultChild, PreschoolRetrospective StudiesInfantAdultSurvival RatePrognosisFollow-Up StudiesCombined Modality TherapyEuropeLymphatic Metastasis

Author keywords

alveolar rhabdomyosarcomachemotherapyfusion‐positive rhabdomyosarcomalocal treatmentlymph node involvementpediatric/adolescent oncology

Substances

Oncogene Proteins, Fusion

Authors and institutions

  • Department of Pediatric Hematology and Oncology, University Children´s Hospital Tuebingen, Tuebingen, Germany.
  • Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin (Olgahospital), Pädiatrie 5 (Pädiatrische Onkologie, Hämatologie, Immunologie), Klinikum der Landeshauptstadt Stuttgart, Stuttgart, Germany.
  • Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin (Olgahospital), Pädiatrie 2 (Pädiatrische Gastroenterologie), Klinikum der Landeshauptstadt Stuttgart, Stuttgart, Germany.
  • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Division of Imaging and Oncology, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands.
  • Network Aging Research, Heidelberg University, Heidelberg, Germany.

ORCID profiles: Amadeus T Heinz, Véronique Minard-Colin, Christian Vokuhl, Ewa Koscielniak, Julia C Chisholm, Monika Sparber-Sauer, Gianni Bisogno

Funding

  • Fondazione Città della Speranza
  • Alice's Arc
  • Deutsche Kinderkrebsstiftung
  • Foerderkreis Krebskranke Kinder Stuttgart
  • German Cancer Aid Foundation
  • Royal Marsden Cancer Charity
  • National Institute for Health Research
  • Royal Marsden NHS Foundation Trust

Cite

APA

Heinz, A. T., Ciuffolotti, M., Merks, J. H. M., Schönstein, A., Minard-Colin, V., Fuchs, J., Guillen, G., Timmermann, B., Vokuhl, C., Koscielniak, E., Chisholm, J. C., Sparber-Sauer, M., & Bisogno, G. (2025). Treatment of Pediatric, Adolescent, and Young Adult Patients With Fusion‐Positive Alveolar Rhabdomyosarcoma Infiltrating Regional Lymph Nodes in the European CWS‐2002P and RMS 2005 Studies and the Soft Tissue Sarcoma Registry. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31476

Vancouver

Heinz AT, Ciuffolotti M, Merks JHM, Schönstein A, Minard-Colin V, Fuchs J, et al. Treatment of Pediatric, Adolescent, and Young Adult Patients With Fusion‐Positive Alveolar Rhabdomyosarcoma Infiltrating Regional Lymph Nodes in the European CWS‐2002P and RMS 2005 Studies and the Soft Tissue Sarcoma Registry. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31476

BibTeX
@article{Heinz2025,
  author = {Heinz, Amadeus T and Ciuffolotti, Melissa and Merks, Johannes H M and Schönstein, Anton and Minard-Colin, Véronique and Fuchs, Jörg and Guillen, Gabriela and Timmermann, Beate and Vokuhl, Christian and Koscielniak, Ewa and Chisholm, Julia C and Sparber-Sauer, Monika and Bisogno, Gianni},
  title = {Treatment of Pediatric, Adolescent, and Young Adult Patients With Fusion‐Positive Alveolar Rhabdomyosarcoma Infiltrating Regional Lymph Nodes in the European CWS‐2002P and RMS 2005 Studies and the Soft Tissue Sarcoma Registry},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31476}
}
Start for free →